NCT03243981

Brief Summary

In this exploratory study, we hope to learn if treatment of broadband light with infrared light can alter the molecular pathways associated with aging. Secondary exploratory objective is to see if there are any visible effects of this light treatment on human skin.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2016

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 20, 2016

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 20, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 20, 2017

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

July 11, 2017

Completed
29 days until next milestone

First Posted

Study publicly available on registry

August 9, 2017

Completed
2.1 years until next milestone

Results Posted

Study results publicly available

October 1, 2019

Completed
Last Updated

October 1, 2019

Status Verified

September 1, 2019

Enrollment Period

7 months

First QC Date

July 11, 2017

Results QC Date

August 15, 2019

Last Update Submit

September 11, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Genes With Significant Change in Gene Transcription

    The endpoint consisted of clinical inspection of biopsies of untreated skin and skin after three treatments. Genes were considered altered if a statistically significant change in transcription of an individual gene was observed between the treated and untreated skin (significance was set at p\<0.01, adjusted for false discovery rate). The values in the table represent the total number of recorded genes with significant change.

    16 weeks

Secondary Outcomes (6)

  • Change From Baseline in Fine Wrinkling Score as a Measure of Skin Rejuvenation

    Baseline, day 84

  • Change From Baseline in Coarse Wrinkling Score as a Measure of Skin Rejuvenation

    Baseline, day 84

  • Change From Baseline in Sagging Score as a Measure of Skin Rejuvenation

    Baseline, day 84

  • Change From Baseline in Physician Global Assessment as a Measure of Skin Rejuvenation

    Baseline, day 84

  • Change From Baseline in Cutometry as a Measure of Skin Rejuvenation

    Baseline, day 84

  • +1 more secondary outcomes

Study Arms (1)

Open label study-- single arm

EXPERIMENTAL

All patients will receive Skintyte treatment as well as Skintyte plus broadband light

Device: Sciton SkinTyte (800-1800 nm) with Broadband Light Technology

Interventions

This device has been used in the clinical setting to reduce cheek and submental laxity. SkinTyte delivers sequentially pulsed light (800-1200 nm, with a filter enabling focus on 590 nm) and broadband light (which can be turned on or off).

Open label study-- single arm

Eligibility Criteria

Age55 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \. Female 2. Age 55 years or older (total 6) 3. Fitzpatrick skin type 2-3 4. Photo-aging at least moderate on the extensor forearms

You may not qualify if:

  • \. Unable to understand and sign informed consent form 2. Unable to comply with study procedures 3. Pregnant or lactating 4. Prior treatment to forearms including topical retinoid, laser treatment, photodynamic treatment, prescription topical agents x 1 month 5. Active skin conditions that precluding treatment including zoster, blistering skin disease, psoriasis, atopic dermatitis, abnormal scarring, skin cancer in the area of study treatment 6. Currently on hormone based therapy (both systemic and topical)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University

Redwood City, California, 94063, United States

Location

Limitations and Caveats

The study did not meet its planned sample size.

Results Point of Contact

Title
Anne Lynn Chang, MD
Organization
Stanford University

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: Application of Skintyte and/or broadband light to skin
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Dermatology

Study Record Dates

First Submitted

July 11, 2017

First Posted

August 9, 2017

Study Start

November 20, 2016

Primary Completion

June 20, 2017

Study Completion

June 20, 2017

Last Updated

October 1, 2019

Results First Posted

October 1, 2019

Record last verified: 2019-09

Data Sharing

IPD Sharing
Will not share

Locations